tafamidis meglumine · Foldrx Pharms · NDA 211996
Vyndaqel
Earliest generic entry, as listed
19 Dec 2026
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7214695, US 7214696.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7214695 | substance, product | 19 Dec 2026 |
| US 7214696 | use U-2524 | 19 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent · 211996-00119 Dec 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211996 · 001 · RLD · discontinued | capsule, oral | 20MG | 19 Dec 2026 |
Expired or delisted (1)
- ODE-237 · 3 May 2026